BMS returned license of anticancer Taxol
BMS Pharmaceutical Korea declared a separation from co-promotion of anticancer Taxol with Boryung Pharm, as well as Baraclude.
According to the industry concerned on the 4th, BMS Pharmaceutical Korea returned the license of anticancer Taxol from Boryung Pharm and has sold the product on its own ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
